Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19024566 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL5035980 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL10757058 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL19024592 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL10537390 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL9362232 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL10406629 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL15650373 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL21853572 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 | |
| SCHEMBL5035738 | 1.00 | ACE (0.57) | ACEACE2L3MBTL1RENGNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | claimed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | claimed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | claimed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | claimed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | claimed |
| EP-3192493-B1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO KK (JP) | 2023-07-12 | — | — | EP | disclosed |
| US-9782336-B2 | Moisturizer and cosmetic containing same | AJINOMOTO CO., INC. (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-3192493-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-20170181947-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO CO., INC. (JP) | 2017-06-29 | — | — | US | disclosed |
| EP-1263730-B1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-6770656-B2 | NEURODEGENERATIVE DISORDERS; ANTIEPILEPTIC AND ANTIISCHEMIC AGENTS; INFERTILITY, CARDIOVASCULAR DISORDERS, RENAL HYPOXIA, HEPATITIS AND AIDS TREATMENT | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2004-08-03 | — | — | US | disclosed |
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | MERCK SERONO SA (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1263730-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | Applied Research Systems ARS Holding N.V. (AN) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060798-A1 | AMINE DERIVATIVES FOR THE TREATMENT OF APOPTOSIS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216427-A1 | Amine derivatives for the treatment of apoptosis | BAD, BAX, BCL2 | ACE 3869/4885ACE2 3998/4885L3MBTL1 2909/4885 |
| US-20170181947-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | PPT1, ACOX1, ALDH18A1 | ACE 2920/4885ACE2 2772/4885L3MBTL1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.